Maytansine, a potent cytotoxic agent with CAS 35846-53-8, has been instrumental in the development of cutting-edge Antibody-Drug Conjugates (ADCs). While Maytansine itself presented challenges for direct clinical use, its derivatives, DM1 (also known as Mertansine or Emtansine) and DM4 (also known as Ravtansine or Soravtansine), have emerged as highly effective cytotoxic payloads. These derivatives retain the potent microtubule-disrupting activity of Maytansine while being chemically modified for optimal conjugation to antibodies, enabling precise targeting of cancer cells.

DM1 is a well-established maytansinoid payload that has been successfully incorporated into FDA-approved ADCs, such as Kadcyla (Trastuzumab Emtansine), used to treat HER2-positive metastatic breast cancer. Kadcyla exemplifies the power of combining a HER2-targeting antibody with the cytotoxic might of DM1, leading to highly effective tumor cell destruction with reduced systemic side effects. The buy price of such advanced intermediates reflects their critical role in developing these life-saving therapies.

DM4, another potent maytansinoid, is gaining prominence as a payload for ADCs targeting different cancer types. Elahere (Mirvetuximab Soravtansine-gynx), which uses DM4, has received accelerated FDA approval for treating folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer. This highlights the versatility of maytansinoids beyond DM1 and their potential in addressing various cancer indications. The search for reliable suppliers for these crucial pharmaceutical intermediates is ongoing as the demand for advanced ADCs increases.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting the advancement of targeted cancer therapy by providing high-quality DM1 and DM4 payloads. As a leading manufacturer and supplier in China, we ensure that our products meet the rigorous standards required for pharmaceutical development. Understanding the specific requirements for these advanced compounds, including their price and availability, is key for companies engaged in ADC development. Our goal is to facilitate the purchase of these critical components, thereby accelerating the journey from laboratory research to clinical application, ultimately benefiting patients worldwide.